|
|
Blood, 11 June 2009, Vol. 113, No. 24, pp. 6148-6152.
Prepublished online as a Blood First Edition Paper on April 16, 2009; DOI 10.1182/blood-2009-02-203687.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Brief report
Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation
Corey Smith1,*,
Naohiro Wakisaka2,*,
Tania Crough1,
Jesse Peet1,
Tomokazu Yoshizaki2,
Leone Beagley1, and
Rajiv Khanna1
1 Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Immunology, Queensland Institute of Medical Research, Brisbane, Australia; and
2 Division of Otolaryngology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan
Activation of the nuclear factor– B pathway by Epstein-Barr virus–encoded latent membrane protein-1 (LMP-1) leads to an up-regulation of the major histocompatibility complex class I antigen–processing pathway. Paradoxically, LMP-1 itself induces a subdominant CD8+ T-cell response and appears to have evolved to avoid immune recognition. Here we show that, although expression of LMP-1 in human cells dramatically enhanced the trans-presentation of CD8+ T-cell epitopes, cis-presentation of LMP-1–derived epitopes was severely impaired. Testing of a series of LMP-1 mutants revealed that deletion of the first transmembrane domain of LMP-1, which prevented self-aggregation, significantly enhanced cis-presentation of T-cell epitopes from this protein, whereas it lost its ability to up-regulate trans-presentation. Interestingly, we also found that cis-presentation of LMP-1 epitopes was rescued by blocking the proteasome function. Taken together, these results delineate a novel mechanism of immune evasion, which renders a virally encoded oncogene inaccessible to the conventional major histocompatibility complex class I pathway limiting its cis-presentation to effector cells.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
|
|